NEW YORK, August 1, 2017 /PRNewswire/ --
If you want a Stock Review on PRGO, IMNP, TNXP or UTHR then come over tohttp://dailystocktracker.com/register/ and sign up for your free customized report today. This Morning's attention is to the Healthcare sector, which includes health care providers and services, health care equipment and supplies, and health care
On Monday, shares in Dublin, Ireland headquartered Perrigo Co. PLC recorded a trading volume of 822,953 shares. The stock ended the session 0.60% higher at $74.92. The Company's shares have gained 1.17% over the previous three months. The stock is trading 2.30% above its 50-day moving average. Moreover, shares of Perrigo, which together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 51.59.
On July 27th, 2017, Perrigo announced that it will release its Q2 2017 financial results on August 10th, 2017. The Company will conduct a conference call, hosted by Perrigo's CEO John T. Hendrickson, at 8:00 a.m. EDT on the same day. The conference call will be available live via webcast under the investor relations section of the Company's website. The free research report on PRGO is available at:
Englewood Cliffs, New Jersey headquartered Immune Pharmaceuticals Inc.'s stock closed the day 1.32% lower at $2.24 with a total trading volume of 65,192 shares. The Company's shares are trading 13.81% below their 50-day moving average. Shares of the Company, which develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology, have an RSI of 35.95.
On July 19th, 2017, Immune Pharma (IMNP) confirmed that it is continuing to structure and pursue a spin-off of Cytovia, Inc., its subsidiary, which is dedicated to the development and commercialization of Oncology drugs and drug candidates, into a separate, stand-alone, publicly-traded company. It is contemplated that a pro rata distribution of shares in Cytovia would be issued to IMNP's shareholders as a dividend. The spin-off is expected to create two, independent, publicly-traded companies with distinct strategic plans, leadership, growth strategies, and operational and development priorities. The complimentary report on IMNP can be downloaded at:
Shares in New York-based Tonix Pharmaceuticals Holding Corp. recorded a trading volume of 38,832 shares. The stock ended yesterday's trading session flat at $3.93. The Company's shares are trading below their 50-day moving average by 7.65%. Furthermore, shares of Tonix Pharma, which engages in developing pharmaceutical products for central nervous system disorders, have an RSI of 30.73.
On July 06th, 2017, Tonix Pharma reported that the US Food and Drug Administration has conditionally accepted the proposed trade name Tonmya for TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) for the management of posttraumatic stress disorder (PTSD). The Company recently launched the Phase-3 HONOR study of Tonmya in military-related PTSD, from which top-line results are expected to be reported in Q2 2018. Visit us today and download our complete research report on TNXP for free at:
Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished Monday's session 0.04% higher at $128.40 with a total trading volume of 391,262 shares. The Company's shares have advanced 4.39% over the previous three months. The stock is trading below its 50-day moving average by 0.13%. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 46.32.
On July 27th, 2017, United Therapeutics announced its financial results for Q2 ended June 30th, 2017. Total net revenues for the quarter were $445 million, net loss was $56 million, and non-GAAP earnings were $199 million. Cost of product sales for Q2 2017 were $19 million; research and development expense was $60 million; and selling, general. and administrative expense was $67 million. Get free access to your technical report on UTHR at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...
Acanthosis nigricans is a skin condition in which discoloration and hyperpigmentation of the skin ...View All